Likewise, the combined use of decitabine with an anti-CD105 therapeutic antibody caused a more durable anti-leukemic effect in a xenograft model of acute myeloid leukemia [28], and Venetoclax, i.e., an oral inhibitor of BCL-2 combined with decitabine or azacitidine, achieved nearly 70% complete remission in treatment-naive, elderly patients with acute myeloid leukemia [29]. Here, BCL2 is linked to acute myeloid leukemia.